Journal of Pharmaceutical Research International,
Currently: the problem of choosing an effective drug approach for cerebroprotection, in case of traumatic brain injury (TBI), remains to be poorly understood. Clinical studies of cerebroprotectors - antagonists of NMDA-receptors indicate the feasibility of their use in practice. In our opinion, for further research, it would be correct to choose a compound that has neuroprotective properties and synthesized under the guidance of Academician M.O. Lozynsky at the Institute of Organic Chemistry of the National Academy of Sciences of Ukraine, a derivative of 1-adamantylethyloxy-3-morpholoin-2-propanol hydroxide (Ademol).
Materials and Methods: The pharmacological action of Ademol was investigated on the example of a simulated TBI at a dose of 2 mg/kg intravenously every 12 hours for 8 days. The control group and pseudooperated animals received NaCl 0,9% at a dose of 2 mg/kg intravenously (i/v), the comparison group received Amantadine sulfate 5 mg/kg. To determine the efficiency and activity of these molecules the activity of the protein S 100 was used.
Results: The dynamics of S 100 protein levels in groups of rats with Ademol and Amantadine sulfate with traumatic brain injury on the 8th day of observation indicates that on the background of the above therapy, the content of the studied marker decreased by an average of 50,8 and 39.9%. Treatment of rats with severe traumatic brain injury with Ademol at a dose of 2 mg/kg (i/v), was probably better than treatment of rats in the control group with saline and amantadine sulfate and better helped to reduce the growth of protein S 100 level, while Ademol exceeded the reference drug at 18,2% (p <0.05).